
Stephen Gottschalk MD
Chair, Dept of BMT & Cellular Therapy, St Jude Children's Research Hospital
Join to View Full Profile
262 Danny Thomas PlMemphis, TN 38105
Phone+1 901-595-3300
Fax+1 901-595-3842
Dr. Gottschalk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 1998 - 2001
- Baylor College of Medicine (Houston)Residency, Pediatrics, 1995 - 1998
- University of Gottingen Faculty of MedicineClass of 1992
Certifications & Licensure
- TN State Medical License 2017 - 2027
- TX State Medical License 2001 - 2026
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) Start of enrollment: 2003 Sep 01
- Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) Start of enrollment: 2007 Aug 01
- LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) Start of enrollment: 2007 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- VDAC2 loss elicits tumour destruction and inflammation for cancer therapy.Sujing Yuan, Renqiang Sun, Hao Shi, Nicole M Chapman, Haoran Hu
Nature. 2025-03-19 - 1 citationsEASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy.Dua'a Zandaki, Subodh Selukar, Yu Bi, Ying Li, Megan Zinsky
Blood Advances. 2025-01-28 - 7 citationsInterleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney
Nature. 2025-01-01
Journal Articles
- EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow TransplantationStephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood
Abstracts/Posters
- CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC ToxicityStephen Gottschalk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing P...Stephen Gottschalk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-CellsStephen Gottschalk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- St. Jude Explores Curative Therapies for Sickle Cell DiseaseAugust 22nd, 2024
- Pan-Cancer Analysis Uncovers a New Class of Promising CAR T--Cell Immunotherapy TargetsMay 3rd, 2024
- Novel Leukaemia Therapy Aims to Treat Sick Kids Before Time Runs OutNovember 14th, 2022
- Join now to see all
Grant Support
- T32 Training Program in Pediatric Immuno-Oncology and ImmunotherapyST. JUDE CHILDREN'S RESEARCH HOSPITAL2022–2027
- T32 Training Program in Pediatric Immuno-Oncology and ImmunotherapyST. JUDE CHILDREN'S RESEARCH HOSPITAL2022–2027
- Enhancing B7-H3-CAR T cell therapy for pediatric solid tumorsST. JUDE CHILDREN'S RESEARCH HOSPITAL2022–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: